RAP1A was recognized as a drug target for an endocellular parasite Leishmania,[96] and it is a substrate of geranylgeranyltransferase (GGTase‐I), which was also proposed as a target for countering parasitic infections.[97] Its paralogue, RAP1B, mediates cAMP‐dependent invasion by Trypanosoma cruzi in host cells.[98]. Here, RAP1A is linked to parasitic infectious disease.